GlassScriptPhysician profile
Rodolfo A Torres
NPI 1649261496
$5,218.97
in general payments reported to CMS, 2019-2025
30 companies · $965 in 2025
The $965 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $92.01 · 2021: $432 · 2022: $1,342 · 2023: $926 · 2024: $1,200 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,017.36 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $781.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $571.32 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $484.43 | 2021-2025 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.70 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $295.34 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $202.70 | 2019-2024 | Heplisav-B |
| Amgen INC. | $192.78 | 2021-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $143.93 | 2022-2023 | |
| Pfizer INC. | $142.69 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $132.14 | 2020-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $117.15 | 2021-2023 | Gardasil 9 |
| Eisai INC. | $107.15 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $86.64 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $84.68 | 2019 | |
| Phadia US INC. | $59.43 | 2020-2023 | Immunocap |
| Amarin Pharma, INC. | $48.40 | 2021-2022 | |
| Astellas Pharma US INC | $47.04 | 2019-2025 | Veozah |
| Corcept Therapeutics | $38.68 | 2025 | Korlym |
| Sanofi Pasteur INC. | $32.55 | 2021-2023 | |
| Dexcom, INC. | $30.73 | 2023 | Dexcom G6 Transmitter |
| Upsher-Smith Laboratories LLC | $29.79 | 2022 | |
| Noven Therapeutics, LLC | $25.76 | 2024 | Xelstrym |
| Atland Pharmaceuticals, LLC | $22.29 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Evoke Pharma, INC. | $17.49 | 2023 | Gimoti |
| Inspire Medical Systems, INC. | $17.20 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.89 | 2022 | |
| Antares Pharma, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.